Biotech startups in Guangdong, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Shanmu SHANMU | Shenzhen | Series A | $14.7M | 2026-05-06 |
| Hongxin Biology | Shenzhen | Series B | $14.0M | 2026-08-13 |
| Artivila Therapeutics | Shenzhen | Series A | $14.7M | 2026-06-23 |
| Medefa | Zhuhai | Series B | $14.9M | 2026-09-02 |
| Salus BioMed | Shenzhen | Series B | $7.0M | 2025-10-09 |
| Xbiome | Shenzhen | Series B | $100.0M | 2021-12-22 |
| EurekaBio | Shenzhen | Series B | $41.7M | 2024-02-21 |
| Vivolight | Nanshanqu | Series E | $13.9M | 2026-06-01 |
8 rows of the CSV in 5 of its 18 columns.
- The 207 biotech startups in Guangdong, China have raised $4.8B in total.
- 47 of them closed their most recent round in the last 12 months, $544.2M combined.
- The largest of those rounds is Syneron's $150.0M Series B, dated March 2026.
- The most recent is Libo Biotech's $15.0M Series A on 30 October 2026.
- SDIC Venture Capital is an investor in 3 of them, more than any other fund.
- Health care is the most common other sector, with 174 companies (84%).
- 32% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (40% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
14 of 207| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
| Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
| Shanmu SHANMU | Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. | Artificial intelligence | Shenzhen | Series A | $14.7M | 2026-05-06 | $16.0M | QF Capital, Hofan Venture, Wanwu Capital +1 | 1 to 10 | 2020 |
| Ningkang Ruizhu | Ningkang Ruizhu develops targeted drugs. | Biotech | Zhuhai | Series A | $14.1M | 2025-12-05 | $25.6M | GF Qianhe Investment, RiverHead Capital, Hanne Capital +1 | 11 to 50 | 2019 |
| Tianchen Biotechnology | Tianchen Biotechnology develops and sells medical products for ophthalmology. | Biotech | Tianjin | Series C | $27.8M | 2025-06-03 | $41.7M | CMB International Capital Corporation | 2018 | |
| Zhiyi Pharmaceutics | Zhiyi Pharmaceutics researches and develops second-generation probiotics and live biotherapeutics. | Biotech | Guangzhou | Series C | $13.8M | 2024-03-28 | Shenzhen Capital Group, SDIC Venture Capital, Sinoking Capital | 51 to 100 | 2013 | |
| Enzymecode Biotechnology | Enzymecode develops and produces brain health nutritional raw materials and food ingredients. | Biotech | Tianjin | Angel | $1.4M | 2023-12-29 | Draper Dragon | 11 to 50 | 2017 | |
| Yuanyi Biotech | Yuanyi Biotech creates artificial microbial technologies and products. | Biotech | Tianjin | Series A | $13.7M | 2023-10-18 | $21.5M | Marathon Venture Partners, Haitang Fund, Ruipeng Touzi | 51 to 100 | 2021 |
| Canton Biologics | Canton Biologics provides biologics contract development and manufacturing outsourcing services. | Biotech | Guangzhou | Series C | $41.3M | 2023-09-13 | $41.7M | SDIC Venture Capital, Rongtuo Capital Management, Taipu Life Sciences Investment | 101 to 250 | 2016 |
| Chipsailing | Chipsailing Technology sells integrated circuits for fingerprint identification. | Biotech | Nanshanqu | Series A | $1.4M | 2017-05-11 | Oriental Fortune Capital, Haiyuan Capital | 11 to 50 | 2015 | |
| iCarbonX Unicorn | iCarbonX is a China-based company that builds artificial intelligence platforms for health data. | Artificial intelligence | Shenzhen | Series A | $45.0M | 2016-07-15 | $200.0M | Share Capital, ProCapital | 51 to 100 | 2015 |
Table 1. Biotech startups in Guangdong, China: the 14 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 207.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Medefa | Medefa uses synthetic biology to mass-produce novel PHA biomaterials. | Biotech | Zhuhai | Series B | $14.9M | 2026-09-02 | $16.3M | Motianshi Touzi, Taiping Innovation | 11 to 50 | 2019 |
| 2 | Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| 3 | Shanmu SHANMU | Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. | Artificial intelligence | Shenzhen | Series A | $14.7M | 2026-05-06 | $16.0M | QF Capital, Hofan Venture, Wanwu Capital +1 | 1 to 10 | 2020 |
| 4 | Ningkang Ruizhu | Ningkang Ruizhu develops targeted drugs. | Biotech | Zhuhai | Series A | $14.1M | 2025-12-05 | $25.6M | GF Qianhe Investment, RiverHead Capital, Hanne Capital +1 | 11 to 50 | 2019 |
| 5 | Hongxin Biology | Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. | Biotech | Shenzhen | Series B | $14.0M | 2026-08-13 | $14.0M | Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group | 11 to 50 | 2021 |
| 6 | Vivolight | Vivolight conducts medical research and develops intravascular interventional imaging technology. | Biotech | Nanshanqu | Series E | $13.9M | 2026-06-01 | $52.2M | CAS Star, TusStar | 51 to 100 | 2012 |
| 7 | Shengqiang Technology | Shengqiang Technology researches, manufactures, and sells high-tech products. | Biotech | Shenzhen | Series C | $13.7M | 2026-07-26 | $13.7M | SDIC Venture Capital | 101 to 250 | 2013 |
Table 2. Biotech startups in Guangdong, China: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | SDIC Venture Capital | Venture capital firm | Xicheng, China | 3 | 1% | 1 | Shengqiang Technology |
| 2 | Oriental Fortune Capital | Venture capital firm | Shenzhen, China | 3 | 1% | ||
| 3 | Haitang Fund | Venture capital firm | Nankai, China | 3 | 1% | 1 | Zhonghe Gene |
| 4 | Kaitai Capital | Venture capital firm | Hangzhou, China | 3 | 1% | ||
| 5 | Haiyuan Capital | Venture capital firm | Shenzhen, China | 2 | 1% | 1 | Hongxin Biology |
| 6 | Shenzhen Capital Group | Venture capital firm | Nanshan, China | 2 | 1% | ||
| 7 | Gaorong Capital | Venture capital firm | Wangjing, China | 2 | 1% | ||
| 8 | Fortune Venture Capital | Venture capital firm | Shenzhen, China | 2 | 1% | ||
| 9 | Shenzhen Guozhong Venture Capital Management | Venture capital firm | Shenzhen, China | 2 | 1% | ||
| 10 | Yael Capital Management Limited | Venture capital firm | Shenzhen, China | 2 | 1% | ||
| 11 | SZHTI Group | Venture capital firm | Shenzhen, China | 2 | 1% | 2 | Newdel Biotech, JGene Biotechnology |
| 12 | Wanwu Capital | Venture capital firm | Beijing, China | 1 | 0% | 1 | Shanmu SHANMU |
| 13 | Glacier Capital | Investment bank | Phoenix, United States | 1 | 0% | 1 | Shanmu SHANMU |
| 14 | QF Capital | Private equity firm | Shenzhen, China | 1 | 0% | 1 | Shanmu SHANMU |
| 15 | Hofan Venture | Venture capital firm | Shenzhen, China | 1 | 0% | 1 | Shanmu SHANMU |
Table 3. Biotech startups in Guangdong, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 174 | 84% | $3.6B |
| Software | 17 | 8% | $662.1M |
| Artificial intelligence | 16 | 8% | $662.1M |
| Hardware | 5 | 2% | $30.6M |
| Energy | 3 | 1% | $816.8M |
| Cybersecurity | 2 | 1% |
Table 4. Biotech startups in Guangdong, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Guangdong, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups in Guangdong, China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 3 | 6% | $55.4M |
| September 2026 | 3 | 6% | $104.3M |
| August 2026 | 7 | 15% | $52.6M |
| July 2026 | 6 | 13% | $28.5M |
| June 2026 | 4 | 9% | $36.0M |
| May 2026 | 3 | 6% | $29.4M |
| April 2026 | 2 | 4% | $29.1M |
| March 2026 | 2 | 4% | $164.5M |
| February 2026 | 2 | 4% | $14.4M |
| January 2026 | 10 | 21% | $15.7M |
| December 2025 | 3 | 6% | $14.1M |
| November 2025 | 2 | 4% |
Table 7. Biotech startups in Guangdong, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 42 | 20% | $530.1M |
| 2025 | 27 | 13% | $279.5M |
| 2024 | 24 | 12% | $185.1M |
| 2023 | 27 | 13% | $252.8M |
| 2022 | 24 | 12% | $1.0B |
| 2021 | 16 | 8% | $442.4M |
Table 8. Biotech startups in Guangdong, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 22 | 11% |
| 2020 to 2022 | 44 | 22% |
| 2015 to 2019 | 86 | 42% |
| 2010 to 2014 | 30 | 15% |
| Before 2010 | 22 | 11% |
Table 9. Biotech startups in Guangdong, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 13 | 8% |
| 11 to 50 | 62 | 40% |
| 51 to 100 | 40 | 26% |
| 101 to 250 | 22 | 14% |
| 251 to 500 | 10 | 6% |
| 501 to 1,000 | 6 | 4% |
| 1,001 to 5,000 | 1 | 1% |
Table 10. Biotech startups in Guangdong, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Guangdong, China. On 16 November 2026 that is 207 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 14 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 207 rows: 88 have no round amount, 0 no city and 78 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Guangdong, China are on the list?
- 207, in the file dated 16 November 2026. 47 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 207 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.